---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022118"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:43:34.878529+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Imunon posts Q3 net loss of $3.4M, cash $5.3M; Phase 3 ovarian cancer study enrollment ahead

## Summary
- Net loss of $3.4M ($1.16/sh) in Q3 2025 vs $4.8M ($3.76/sh) in Q3 2024; operating expenses down 30% to $3.5M.
- Cash and equivalents $5.3M as of Sept 30, 2025; $4.5M raised from warrant exercises and ATM; runway into Q1 2026.
- Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer enrollment exceeding expectations; Phase 2 data showed 13-month OS benefit.
- R&D Day on Nov 10 highlighted investigator optimism and translational data; new data presented at SITC and AACR.
- PlaCCine DNA vaccine platform proof-of-concept data presented; actively seeking partnerships.

## SEC filing metadata
- accession: 0001493152-25-022118
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315225022118/0001493152-25-022118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315225022118/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022118
- JSON: https://secwatch.observer/filing/0001493152-25-022118.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.